Sophie Lena Stocker - Toxicology

Author Information

Sophie Lena Stocker is a renowned expert in the field of Clinical Pharmacology and Toxicology. She is affiliated with the Department of Clinical Pharmacology and Toxicology at St. Vincent's Hospital in Sydney, NSW, Australia. Her work is pivotal in advancing the understanding and application of pharmacological practices in clinical settings.

Research Contributions

Dr. Sophie Lena Stocker has made significant contributions to the field through her extensive research work. Her studies cover a wide range of topics, including therapeutic drug monitoring, pharmacogenomics, and the clinical applications of various drug therapies such as Sodium-glucose co-transporter 2 inhibitors and Tacrolimus therapy in heart transplant recipients. Her research is instrumental in improving clinical practices and drug therapy adherence, as well as enhancing the predictive performance of dosing models.

Aliases

Sophie Lena Stocker is recognized by several variations of her name in academic publications, including Sophie L. Stocker, Sophie Stocker, S. L. Stocker, and S L Stocker. These aliases are used interchangeably across her numerous publications and collaborations.

Publication and Citation Metrics

Metric	Value
Total Papers	104
Total Citations	2194
H-index	23

Publications:

Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction.

DOI: 10.1111/imj.15727

Year: 2022

Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals.

DOI: 10.1111/imj.15719

Year: 2022

Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review.

DOI: 10.1093/ijpp/riac025

Year: 2022

Would they accept it? An interview study to identify barriers and facilitators to user acceptance of a prescribing advice service

DOI: 10.1186/s12913-022-07927-1

Year: 2022

Tacrolimus Therapy in Adult Heart Transplant Recipients: Evaluation of a Bayesian Forecasting Software.

DOI: 10.1097/FTD.0000000000000909

Year: 2021

Erratum: A Model Averaging/Selection Approach Improves the Predictive Performance of Model‐Informed Precision Dosing: Vancomycin as a Case Study

DOI: 10.1002/cpt.2353

Year: 2021

Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

DOI: 10.1097/FTD.0000000000000931

Year: 2021

779-P: Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists

DOI: 10.2337/db21-779-p

Year: 2021

Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

DOI: 10.1097/FTD.0000000000000944

Year: 2021

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists.

DOI: 10.1016/j.diabres.2021.109036

Year: 2021

How Does DSHEA Impact Toxicology?

What Are Some Recent Advances in Toxicological Assessment?

What is DTPA?

How Does the Body Respond to Cellular Damage?

What Should You Do If You Suspect Your Pet Has Been Poisoned?

How can Entrez facilitate interdisciplinary collaboration in toxicology?

What is a Database Management System in Toxicology?

What is the Society of Toxicology (SOT) Annual Meeting?

What is Graphitic Carbon Nitride?

How Does fMRI Work?

Partnered Content Networks

Relevant Topics